Yosprala is a drug owned by Genus Life Sciences Inc. It is protected by 5 US drug patents filed from 2016 to 2018. Out of these, 2 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 13, 2033. Details of Yosprala's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Yosprala's patents.

Latest Legal Activities on Yosprala's Patents

Given below is the list of recent legal activities going on the following patents of Yosprala.

Activity	Date	Patent Number
Today's Legal Activities
Maintenance Fee Reminder Mailed Critical	12 Feb, 2024	US8206741
Expire Patent Critical	11 Jul, 2022	US9987231
Maintenance Fee Reminder Mailed Critical	24 Jan, 2022	US9987231
Payment of Maintenance Fee, 4th Year, Large Entity	10 Sep, 2020	US9539214
Surcharge for Late Payment, Large Entity	10 Sep, 2020	US9539214
Maintenance Fee Reminder Mailed Critical	31 Aug, 2020	US9539214
Payment of Maintenance Fee, 8th Year, Large Entity	26 Dec, 2019	US8206741
Email Notification Critical	18 Mar, 2019	US8206741
Change in Power of Attorney (May Include Associate POA) Critical	18 Mar, 2019	US8206741
Email Notification Critical	14 Mar, 2019	US6926907 (Litigated)

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Yosprala and ongoing litigations to help you estimate the early arrival of Yosprala generic.

Yosprala's Litigations

Yosprala been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 21, 2015, against patent number US6926907. The petitioner Coalition for Affordable Drugs VII LLC, challenged the validity of this patent, with POZEN Inc. as the respondent. Click below to track the latest information on how companies are challenging Yosprala's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US6926907	May, 2015	Institution Denied (08 Dec, 2015)	POZEN Inc. et al.	Coalition for Affordable Drugs VII LLC et al.
US6926907	May, 2015	Terminated-Denied (08 Dec, 2015)	POZEN Inc.	Coalition for Affordable Drugs VII LLC

FDA has granted some exclusivities to Yosprala. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Yosprala, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Yosprala.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Yosprala's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Yosprala's generic, the next section provides detailed information on ongoing and past EP oppositions related to Yosprala patents.

Yosprala's Oppositions Filed in EPO

Yosprala has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 15, 2011, by Strawman Limited. This opposition was filed on patent number EP02734602A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP02734602A	Apr, 2011	CHATFIELD PHARMACEUTICALS LIMITED	Patent maintained as amended
EP02734602A	Apr, 2011	STRAWMAN LIMITED	Patent maintained as amended

US patents provide insights into the exclusivity only within the United States, but Yosprala is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Yosprala's family patents as well as insights into ongoing legal events on those patents.

Yosprala's Family Patents

Yosprala has patent protection in a total of 25 countries. It's US patent count contributes only to 39.7% of its total global patent coverage. 12 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Yosprala.

Unlock Global Patents

Generic Launch

About Yosprala

Yosprala is a drug owned by Genus Life Sciences Inc. It is used for secondary prevention of cardiovascular and cerebrovascular events in patients at risk of developing aspirin-associated gastric ulcers, as well as for the treatment of cardiovascular disease, cardiovascular events, cerebrovascular events, and risk-reduction of aspirin-associated gastric ulcers. Yosprala uses Aspirin; Omeprazole as an active ingredient. Yosprala was launched by Genus Lifesciences in 2016.